Back to top
more

Insmed (INSM)

(Real Time Quote from BATS)

$24.89 USD

24.89
41,573

-0.03 (-0.12%)

Updated Apr 26, 2024 10:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for INSM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insmed, Inc. [INSM]

Reports for Purchase

Showing records 1 - 20 ( 112 total )

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

04/18/2024

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/23/2024

Company Report

Pages: 8

Near-Term Expected 2Q24 Catalysts For Phase 3 ASPEN Trial and TPIP; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for INSM 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

10/27/2023

Company Report

Pages: 7

Dose Titration and Safety Insights Support TPIP - As ARISE Advances Arikayce With PRO Validation; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

09/06/2023

Daily Note

Pages: 4

ARISE Trial Delivers With Respiratory PRO - Setting Stage for ENCORE; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/04/2023

Company Report

Pages: 7

2023 As the Year of Near-Term Catalysts, Arikayce Growth; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

05/09/2023

Company Report

Pages: 7

Turning New Page For Translational Pillar-Gene Therapy and Rare Disease Upside; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

02/24/2023

Company Report

Pages: 7

Arikayce Global Expansion and 2023 Catalysts For Broader Pipeline; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/28/2022

Company Report

Pages: 7

Arikayce Opportunity Beyond Refractory-PRO Validation Expected 1H23; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/05/2022

Company Report

Pages: 7

Arikayce Delivers for the Quarter-Pipeline Opportunities for 2022 Growth

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

06/22/2022

Industry Report

Pages: 7

KOL Call Highlights: Insights into the PAH Commercial & Clinical Landscape

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/06/2022

Company Report

Pages: 8

Considerations on TPIP Ahead of Phase 2a Readout YE22 and Brensocatib Utility

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

02/18/2022

Company Report

Pages: 7

Arikayce and Pipeline Positioned for Growth—Translational Clarity YE22

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

10/29/2021

Company Report

Pages: 8

Arikayce Ex-US Progress, As Translational Pillar Reflects Pipeline Future

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

10/08/2021

Company Report

Pages: 8

Considerations for Arikayce Progress, Complemented by Broader Pipeline; Reit Buy and $52 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

10/07/2021

Industry Report

Pages: 6

Highlights from PAH Evolving Landscape KOL Call: Need for Novel Mechanisms

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 12.50

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for INSM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/06/2021

Company Report

Pages: 7

Broader Pipeline Continues to Emerge From the Arikayce Spotlight

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/07/2021

Company Report

Pages: 8

Arikayce Global Expansion Complimented by Pipeline Progress; TPIP Data Expected 2H21

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

02/26/2021

Company Report

Pages: 7

ARIKAYCE Continues to March Foward; While Brensocatib May Have Hidden Oncology Play

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party